Davunetide vs N-Acetyl Semax

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.

Same ACTH(4-7) core as Semax, but structural modifications resist peptidase degradation. Enhances BDNF expression, supports dopaminergic and serotonergic neurotransmission, and modulates NMDA receptor activity.

N-Acetyl-Semax is an acetylated derivative of semax (MEHFPGP), the synthetic ACTH(4-7)PGP heptapeptide nootropic and neuroprotective compound developed in Russia; N-acetylation is proposed to improve enzymatic stability and CNS pharmacokinetics relative to the parent compound, with the expectation that the acetylated form retains semax receptor interactions and neurotrophic effects with potentially greater bioavailability. Semax itself modulates BDNF and NGF expression, influences dopaminergic and serotonergic activity, and has been studied in Russian clinical trials for ischemic stroke and cognitive disorders; N-acetyl-semax is marketed as an enhanced analog on the basis of these parent compound properties. No publications indexed in PubMed specifically examine N-acetyl-semax as a distinct compound; no human clinical trials, independent preclinical studies, or pharmacokinetic data for this specific acetylated form appear in the indexed scientific literature, meaning all claims about this compound are extrapolations from the parent compound evidence base. N-Acetyl-Semax has no FDA approval and no approved indication in any jurisdiction; it is available through research chemical suppliers as an analog of a Russia-approved compound, but its independent pharmacological properties and human safety profile are entirely uncharacterized as a distinct molecule. Semax variant landscape: N-Acetyl-Semax sits alongside several related analogs in the research compound market. The base compound semax (approved in Russia, primarily used intranasally) is the most evidence-backed form. Semax amidate and N-acetyl semax amidate add C-terminal amidation — another stability modification proposed to further reduce enzymatic cleavage. Research suppliers sometimes list "N-Acetyl Semax Amidate" as a combined modification compound. All variant claims trace back to the parent semax pharmacology; independent validation of each structural modification's effect on human CNS pharmacokinetics does not exist in published literature. Administration: N-Acetyl-Semax is most commonly used as a nasal spray solution, mirroring the intranasal route of approved semax in Russia. This route is proposed to allow absorption via the olfactory epithelium for partial CNS delivery. Cognitive peptide providers offering semax-class compounds are listed in the PeptideBase cognitive peptides directory.